Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | GHSR | Q92847 | 11/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989098 | 0.84 | GHSR (0.49) | GHSRPOLBL3MBTL1PKMALDH1A1 | |
| SCHEMBL13245993 | 0.82 | KDM4E (0.48) | GHSRL3MBTL1PKMKDM4E | |
| SCHEMBL2990049 | 0.81 | LMNA (0.47) | GHSRPKMALDH1A1KITCA1 | |
| SCHEMBL2989516 | 0.81 | GHSR (0.50) | GHSRL3MBTL1 | |
| SCHEMBL2985998 | 0.79 | GHSR (0.51) | GHSRALDH1A1 | |
| SCHEMBL2997886 | 0.78 | KDM4E (0.47) | GHSRL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL28509972 | 0.78 | HTR6 (0.69) | HTR6POLBPKMALDH1A1CA1 | |
| SCHEMBL4664054 | 0.74 | KDM4E (0.45) | GHSRKDM4EALDH1A1KIT | |
| SCHEMBL4664000 | 0.74 | LMNA (0.45) | HTR6GHSRL3MBTL1PKMALDH1A1 | |
| SCHEMBL2979801 | 0.73 | ALDH1A1 (0.50) | GHSRPOLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | BLANEY EMMA LOUISE | 2010-07-15 | — | — | US | disclosed |
| EP-2007716-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118852-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | HTR6 158/4885GHSR 1/4885POLB 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.